Oncotect vs PetDx and Volition

Oncotect vs PetDx and Volition

Oncotect emerges as a cutting-edge company at the forefront of veterinary diagnostics, introducing a non-invasive, multi-cancer screening test designed to revolutionize canine healthcare. This innovative test promises a range of unparalleled benefits not found in existing options like PetDx and Volition. Offering the unique advantage of multi-cancer detection, Oncotect’s test shows high accuracy, ensuring reliable results crucial for informed decision-making. The emphasis on convenience through a non-invasive approach reduces stress and discomfort for dogs, fostering greater compliance with regular screenings. Moreover, the test’s reported cost-effectiveness opens doors for more accessible and widespread cancer screening among pet owners, potentially leading to early detection and improved treatment outcomes. 

In an era where early intervention is paramount, Oncotect’s commitment to non-invasiveness, accuracy, and comprehensive screening heralds a promising stride toward enhancing the overall well-being of our canine companions.

Oncotect vs PetDx vs Volition

On one hand, PetDx, a San Diego-headquartered molecular diagnostics firm, employs human liquid biopsy technology to identify cancer in dogs. The primary offering, OncoK9, allows veterinarians to identify canine cancer through a blood draw. Nevertheless, this procedure is undeniably invasive, requiring 15 ml of blood. Moreover, its precision is constrained, displaying a sensitivity of 54.7% and a specificity of 98.4% across 30 types of canine cancer. Moreover, the elevated cost of the test, priced at $1,000 in the retail market, may pose a significant financial hurdle for numerous pet parents.

On the other hand, Volition, an epigenetics enterprise, is in the process of creating blood tests for the diagnosis of various cancers and other illnesses. Their Nu.Q Vet Cancer Screening Test employs an Enzyme-Linked Immunosorbent Assay (ELISA) based screening blood test, aiming to simplify the diagnostic procedure, especially for older or at-risk dogs. However, it’s indubitably important to note that this test, like others, involves an invasive blood draw. At present, it can identify lymphoma with a sensitivity of 77%, hemangiosarcoma with 82% sensitivity, and histiocytic sarcoma with 54% sensitivity.

In contrast to other available cancer screening options mentioned above, Oncotect’s test stands out by offering a comprehensive set of advantages. From 2021 to 2023, a two-year longitudinal clinical study, conducted in collaboration with local veterinary hospitals and involving a cohort of over 500 canines, provided valuable insights. The data gleaned from this extensive study reveal an impressive sensitivity of 83% and a specificity of 96% specifically for the four most common canine cancer types: lymphoma, melanoma, hemangiosarcoma, and mast cell tumors. These findings underscore the remarkable accuracy achieved through the diagnostic methodologies employed for these prevalent canine neoplasms. 

Notably, the Oncotect test sets itself apart by being convenient, requiring only a simple urine sample, and cost-effective, with a retail price of $199, offering a stark contrast to traditional methods that can incur costs of $700 or more. Moreover, the non-invasive nature of the test, which eliminates the need for needles, contributes to its appeal, allowing for early screening even before any clinical signs of cancer manifest.

Oncotect’s commitment to pioneering technology is evident in the amalgamation of accuracy, convenience, and cost-effectiveness, making it a promising contender in the realm of canine cancer screening.

With all these, Oncotect’s test emerges as the exclusive cancer screening option capable of delivering benefits across all six crucial areas, surpassing competitors like PetDx and Volition, which, at most, provide three or four advantages. By introducing a non-invasive, multi-cancer screening test that is both convenient and cost-effective, Oncotect has positioned itself as a groundbreaking solution for pet owners seeking an advanced and comprehensive approach to detecting cancer in their beloved companions. This innovative offering not only represents a significant leap forward in veterinary diagnostics but also underscores Oncotect’s commitment to providing pet owners with a holistic and cutting-edge solution for the early detection of canine cancer.